Literature DB >> 26990633

Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS.

Chaoran Yin1, Ting Zhang, Fang Li, Fan Yang, Raj Putatunda, Won-Bin Young, Kamel Khalili, Wenhui Hu, Yonggang Zhang.   

Abstract

OBJECTIVE: There is an urgent need for the development of HIV-1 genome eradication strategies that lead to a permanent cure for HIV-1/AIDS. We previously reported that four guide RNAs (gRNAs) targeting HIV-1 long terminal repeats (LTR) effectively eradicated the entire HIV-1 genome. In this study, we sought to identify the best gRNAs targeting HIV-1 LTR and viral structural region and optimize gRNA pairing that can efficiently eradicate the HIV-1 genome.
DESIGN: Highly specific gRNAs were designed using bioinformatics tools, and their capacity of guiding CRISPR-associated system 9 to cleave HIV-1 proviral DNA was evaluated using high-throughput HIV-1 luciferase reporter assay and rapid Direct-PCR genotyping.
METHODS: The target seed sequences for each gRNA were cloned into lentiviral vectors. HEK293T cells were cotransfected with a pEcoHIV-NL4-3-firefly-luciferase reporter vector (1 : 20) over lentiviral vectors carrying CRISPR-associated system 9 and single gRNA or various combinations of gRNAs. The EcoHIV DNA cleaving efficiency was evaluated by Direct-PCR genotyping, and the EcoHIV transcription/replication activity was examined by a luciferase reporter assay.
RESULTS: Most of the designed gRNAs are effective to eliminate the predicted HIV-1 genome sequence between the selected two target sites. This is evidenced by the presence of PCR genotypic deletion/insertion and the decrease of luciferase reporter activity. In particular, a combination of viral structural gRNAs with LTR gRNAs provided a higher efficiency of genome eradication and an easier approach for PCR genotyping.
CONCLUSION: Our screening strategy can specifically and effectively identify gRNAs targeting HIV-1 LTR and structural region to excise proviral HIV-1 from the host genome.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26990633      PMCID: PMC4851589          DOI: 10.1097/QAD.0000000000001079

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  67 in total

1.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  Visualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.

Authors:  Jiasheng Song; Zhengxin Cai; Alexander G White; Tao Jin; Xiaolei Wang; Deepak Kadayakkara; Carolyn J Anderson; Zandrea Ambrose; Won-Bin Young
Journal:  J Gen Virol       Date:  2015-07-14       Impact factor: 3.891

3.  Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells.

Authors:  Hsin-Kai Liao; Ying Gu; Arturo Diaz; John Marlett; Yuta Takahashi; Mo Li; Keiichiro Suzuki; Ruo Xu; Tomoaki Hishida; Chan-Jung Chang; Concepcion Rodriguez Esteban; John Young; Juan Carlos Izpisua Belmonte
Journal:  Nat Commun       Date:  2015-03-10       Impact factor: 14.919

4.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

5.  Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases.

Authors:  Hyung Joo Lee; Jiyeon Kweon; Eunji Kim; Seokjoong Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2011-12-19       Impact factor: 9.043

6.  CRISPR-STAT: an easy and reliable PCR-based method to evaluate target-specific sgRNA activity.

Authors:  Blake Carrington; Gaurav K Varshney; Shawn M Burgess; Raman Sood
Journal:  Nucleic Acids Res       Date:  2015-08-07       Impact factor: 16.971

7.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

8.  A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity.

Authors:  Claudio Mussolino; Robert Morbitzer; Fabienne Lütge; Nadine Dannemann; Thomas Lahaye; Toni Cathomen
Journal:  Nucleic Acids Res       Date:  2011-08-03       Impact factor: 16.971

9.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.

Authors:  Prashant Mali; John Aach; P Benjamin Stranges; Kevin M Esvelt; Mark Moosburner; Sriram Kosuri; Luhan Yang; George M Church
Journal:  Nat Biotechnol       Date:  2013-08-01       Impact factor: 54.908

10.  Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Authors:  Datsen George Wei; Vicki Chiang; Elizabeth Fyne; Mini Balakrishnan; Tiffany Barnes; Michael Graupe; Joseph Hesselgesser; Alivelu Irrinki; Jeffrey P Murry; George Stepan; Kirsten M Stray; Angela Tsai; Helen Yu; Jonathan Spindler; Mary Kearney; Celsa A Spina; Deborah McMahon; Jacob Lalezari; Derek Sloan; John Mellors; Romas Geleziunas; Tomas Cihlar
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

View more
  37 in total

1.  A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness.

Authors:  K E Yoder
Journal:  Acta Virol       Date:  2019       Impact factor: 1.162

Review 2.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

Review 3.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

4.  Combinatorial CRISPR-Cas9 and RNA Interference Attack on HIV-1 DNA and RNA Can Lead to Cross-Resistance.

Authors:  Na Zhao; Gang Wang; Atze T Das; Ben Berkhout
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

5.  In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.

Authors:  Chaoran Yin; Ting Zhang; Xiying Qu; Yonggang Zhang; Raj Putatunda; Xiao Xiao; Fang Li; Weidong Xiao; Huaqing Zhao; Shen Dai; Xuebin Qin; Xianming Mo; Won-Bin Young; Kamel Khalili; Wenhui Hu
Journal:  Mol Ther       Date:  2017-03-30       Impact factor: 11.454

Review 6.  CRISPR Editing Technology in Biological and Biomedical Investigation.

Authors:  Martyn K White; Rafal Kaminski; Won-Bin Young; Pamela C Roehm; Kamel Khalili
Journal:  J Cell Biochem       Date:  2017-07-04       Impact factor: 4.429

Review 7.  Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed.

Authors:  Jeffrey M Jacobson; Kamel Khalili
Journal:  AIDS Rev       Date:  2018       Impact factor: 2.500

8.  Multiplexed Simian Immunodeficiency Virus-Specific Paired RNA-Guided Cas9 Nickases Inactivate Proviral DNA.

Authors:  Lisa M Smith; Jason T Ladner; Vida L Hodara; Laura M Parodi; R Alan Harris; Jessica E Callery; Zhao Lai; Yi Zou; Muthuswamy Raveedran; Jeffrey Rogers; Luis D Giavedoni
Journal:  J Virol       Date:  2021-09-22       Impact factor: 5.103

9.  Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.

Authors:  Will Dampier; Neil T Sullivan; Joshua Chang Mell; Vanessa Pirrone; Garth D Ehrlich; Cheng-Han Chung; Alexander G Allen; Mathew DeSimone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Zsofia Szep; Kamel Khalili; Jeffrey M Jacobson; Michael R Nonnemacher; Brian Wigdahl
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-27       Impact factor: 2.205

Review 10.  CRISPR/Cas technology as a promising weapon to combat viral infections.

Authors:  Carmen Escalona-Noguero; María López-Valls; Begoña Sot
Journal:  Bioessays       Date:  2021-02-11       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.